Skip to main content
SpringerLink
Log in

Grundlagen und Grenzen der endokrinen Therapie des fortgeschrittenen Prostatakarzinoms

  • Conference paper
Behandlung des fortgeschrittenen Prostatakarzinoms

  • 21 Accesses

Zusammenfassung

Obwohl der Einfluß des Hodens auf Wachstum und Funktion der Prostata bereits im 19. Jahrhundert vermutet worden war, konnte dies erst durch die Pionierarbeiten von Huggins u. Stevens bestätig werden. Es entstand das Konzept der Androgenabhängigkeit des Prostatagewebes [14].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Asselin J, Labrie F, Gourdeau J, Bonne C, Raynaud JP (1976) Binding of 3H-methyltrienolone (R-1881) in rat prostate und human benign prostatic hypertrophy ( BPH ). Steroids 28: 449459

    Google Scholar 

  2. Barrack ER, Coffey DS (1980) The specific binding of estrogens and androgens to the nuclear matrix of sex hormone responsive tissues. J Biol Chem 255: 7265–7275

    PubMed  CAS  Google Scholar 

  3. Bartsch G, Müller HR, Oberholzer M, Rohr HP (1979) Light microscopic stereological analysis of the normal human prostate and of benign prostate hyperplasia. J Urol 122: 487491

    Google Scholar 

  4. Bonne C, Raynaud JP (1975) Methyltrienolone, a specific ligand for cellular androgen receptors. Steroids 26:227.-232

    Google Scholar 

  5. Bruchovsky N, Lesser B, Van Doom E, Craven S (1975) Hormonal effects on cell proliferation in rat prostate. Vitam Horm 33: 61–102

    Article  PubMed  CAS  Google Scholar 

  6. Bruchovsky N, Callaway T, Lieskovsky G, Rennie PS (1980) Markers of androgen action in human prostate: potential use in the clinical assessment of prostatic carcinoma. In: Witliff JL, Dapunt O (eds) Steroid receptors and hormone dependent neoplasia. Masson Publ USA, New York, pp 121–132

    Google Scholar 

  7. Caine M, Perlberg S, Gordon R (1975) The treatment of benign prostatic hypertrophy with flutamide (SCH-13521): A placebo controlled study. J Urol 114: 564–568

    Google Scholar 

  8. Corbin A (1982) From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents. Yale J Biol Med 55: 27–47

    PubMed  CAS  Google Scholar 

  9. Cowan RA, Cowan SK, Grant JK, Elder HY (1977) Biochemical investigations of separated epithelium and stroma from benign prostatic hyperplastic tissue. J Endocrinol 74: 111–116

    Article  PubMed  CAS  Google Scholar 

  10. De Krester DM, Catt KJ, Paulsen CA (1971) Studies on the in vitro testicular binding of iodinated luteinizing hormone in rats. Endocrinology 80: 332–337

    Google Scholar 

  11. Dhom G (1976) Pathology and classification of prostatic carcinoma. In: Marberger H, Haschek H, Schirmer HKA, Colston JAC, Witkin E (eds) Prostatic disease. Liss, New York, p 111

    Google Scholar 

  12. Dufau ML, Catt KJ (1973) Extraction of soluble gonadotropin from rat testis. Nature 242: 246–248

    CAS  Google Scholar 

  13. Huggins C, Hodge CV (1941) Studies on prostatic cancer. I. The Effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293–297

    Google Scholar 

  14. Huggins C, Stevens RA (1940) The effect of castration on benign hypertrophy of the prostate in man. J Urol 43: 705–714

    Google Scholar 

  15. Huggins C, Stevens RA, Hodges CV (1941) Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43: 209–223

    Google Scholar 

  16. Isaacs JT (1982) Cellular factors in the development of resistance to hormonal therapy. In: Bruchovsky N, Goldie JH (eds) Drug und hormone resistance in neoplasia. vol I. CRC Press, Boca Raton, pp 139–156

    Google Scholar 

  17. Isaacs JT, Coffey DS (1979) Androgenic control of prostatic growth: regulation of steroid levels. UICC Monogr (Prostatic Cancer) 48: 112–122

    CAS  Google Scholar 

  18. Isaacs JT, Coffey DS (1981) Adaptation versus selection on the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 41: 5070–5075

    PubMed  CAS  Google Scholar 

  19. Isaacs JT, Coffey DS (1981) Androgen metabolism in the prostate: new concepts related to normal and abnormal growth. In: Altwein JE, Bartsch G, Jacobi GH (eds) Antihormone, Bedeutung in der Urologie. Zuckschwerdt, München, pp 3–20

    Google Scholar 

  20. Isaacs JT, Heston WDW, Weissmann RM, Coffey DS (1978) Animal models of the hormone-sensitive and insensitive prostatic adenocarcinomas. Dunning R-3327-H, R-3327-HI, and R3327-AT. Cancer Res 38: 4353–4359

    PubMed  CAS  Google Scholar 

  21. Isaacs JT, Schulze H, Coffey DS (1987) Development of androgen resistance in prostatic cancer. In: Murphey GP, Khoury S, Küss R, Chatelain C, Denis L (eds) Prostate cancer, part A: Research, endocrine treatment, and histopathology. Liss, New York, pp 21–31

    Google Scholar 

  22. Jacobi GH, Altwein JE (1980) Androgenstoffwechsel im Prostatakarzinom: 3-Hydroxysteroid-Dehydrogenase-Aktivität in Abhängigkeit vom Tumor-Differenzierungsgrad. Urol Intern 35: 194–205

    Article  CAS  Google Scholar 

  23. Jacobo E, Schmidt JD, Weinstein SH, Flocks RH (1976) Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated prostatic cancer. Urology 8: 231–233

    Article  PubMed  CAS  Google Scholar 

  24. Krieg M, Klötzl G, Kaufmann J, Voigt KD (1981) Stroma of human benign prostatic hyperplasia: preferential tissue for androgen metabolism and estrogen binding. Acta Endocrinol 96: 422–432

    PubMed  CAS  Google Scholar 

  25. Ling V (1982) Genetic basis of drug resistance in mammalian cells. In: Bruchovsky N, Goldie JH (eds) Drug and hormone resistance in neoplasia, vol I. CRC Press, Boca Raton, pp 1–19

    Google Scholar 

  26. MacDonald PC, Madden JD, Brenner PF, Wilson JD, Siiteri PK (1979) Origin of estrogen in normal men and in women with testicular feminisation. J Clin Edocrinol Metab 49: 905–916

    Article  CAS  Google Scholar 

  27. Mackler MA, Liberti JP, Smith MJV, Koontz WW, Prout GR (1972) The effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in patients with carcinoma of the prostate. Invest Urol 9: 423–425

    PubMed  CAS  Google Scholar 

  28. Means AR, Vaitukaitis JL (1972) Peptide hormone receptors: specific binding of 3H-FSH to testis. Endocrinology 90: 39–46

    Article  PubMed  CAS  Google Scholar 

  29. Menon M, Tananis CE, Hicks LL, Hawkins EF, McLoughlin HG, Walsh PC (1978) Characterization of the binding of a potent synthetic androgen methyltrienolone, to human tissues. J Clin Invest 61: 150–162

    Article  PubMed  CAS  Google Scholar 

  30. Morfin RF, Leav I, Chavles JF, Cavazos LF, Ofner P, Floch HH (1977) Correlative study of the morphology and C19-steroid metabolism of benign and cancerous human prostatic tissue. Cancer 39: 1517–1534

    Article  PubMed  CAS  Google Scholar 

  31. Nesbit RM, Baum WC (1950) Endocrine control of prostatic carcinoma; clinical and statistical survey of 1818 cases. JAMA 143: 1317–1320

    CAS  Google Scholar 

  32. Prout GR, Irwin RJ, Kliman B, Daly JJ, MacLaughlin RA, Griffin PP (1975) Prostatic cancer and SCH-13521. II. Histological alterations and the pituitary gonadal axis. J Urol 113: 834840

    Google Scholar 

  33. Prout GR, Kliman B, Daly JJ, MacLaughlin RA, Griffin PD (1976) In vitro uptake of 3H-testosterone and its conversion to dihydrotestosterone by prostatic carcinoma and other tissues. J Urol 116: 603–610

    PubMed  CAS  Google Scholar 

  34. Rennie PS (1982) Biochemical aspects of androgen resistance. In: Bruchovsky N, Goldie JH (eds) Drug and hormone resistance in neoplasia, vol I. CRC Press, Boca Raton, pp 95–121

    Google Scholar 

  35. Robinson MRG, Thomas BS (1971) Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. Br Med J 4: 391–394

    Article  PubMed  CAS  Google Scholar 

  36. Rohr HP, Bartsch G (1980) Human benign prostatic hyperplasia: a stromal disease. Urology 16: 625–633

    Article  PubMed  CAS  Google Scholar 

  37. Romijn JC, Oishi K, Belt de Vries J, Schweikert U, Mulder E, Schröder FH (1980) Androgen metabolism and androgen receptors in separated epithelium and stroma of the human prostate. In: Schröder FH, de Voogd HJ (eds) Steroid receptors, metabolism and prostatic cancer. Excerpta Medica, Amsterdam, pp 134–139

    Google Scholar 

  38. Rosen V, Jung I, Baulieu EE, Roberl P (1975) Androgen binding proteins in human benign prostate hypertrophy. J Clin Endocrinol Metab 41: 761–770

    Article  PubMed  CAS  Google Scholar 

  39. Schally AV, Arimura A, Kastin AJ (1973) The LH and FSH releasing hormone. In: Scow RO (ed) Endocrinology. Excerpta Medica, Amsterdam

    Google Scholar 

  40. Scheiber K, Mikuz G, Bartsch G (1984) Exocrine and endocrine functions in unilateral testicular.disease. World J Urol 2: 251–254

    Article  Google Scholar 

  41. Schulze H, Isaacs JT, Coffey DS (1986) A critical review of the concept of total androgen ablation in the treatment of prostate cancer. In: Murphy G (ed) 2nd International Symposium on Prostatic Cancer. Liss, New York

    Google Scholar 

  42. Scott WW, Menon M, Walsh PC (1980) Hormonal therapy of prostatic cancer. Cancer 45: 1929–1936

    PubMed  CAS  Google Scholar 

  43. Shain SA, Boesel RW (1978) Human prostate steroid hormone receptor quantitation: current methodology and possible utilization as a clinical discriminant in carcinoma. Invest Urol 16: 169–174

    PubMed  CAS  Google Scholar 

  44. Shain SA, Boesel RW (1978) Androgen receptor content of the normal and hyperplastic canine prostate. J Clin Invest 61: 645–660

    Article  Google Scholar 

  45. Shain SA, Boesel RW, Lamm DL, Rodwin HM (1978) Characterization of unoccupied (R) and occupied ( RA) androgen binding components of the hyperplastic human prostate. Steroids 31: 541–556

    Google Scholar 

  46. Shearer RJ, Hendry WF, Sommer IF, Ferguson JD (1973) Plasma testosterone: An accurate monitor of hormone treatment in prostatic cancer. Br J Urol 45: 668–677

    Google Scholar 

  47. Siiteri PK, Wilson JD (1970) Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest 49: 1737–1745

    Google Scholar 

  48. Sirett DAN, Grant JK (1978) Androgen binding in cytosols and nuclei of human benign hyperplastic tissue. J Endocrinol 77: 101–110

    Article  Google Scholar 

  49. Skipper HE, Schabel FM, Lloyd MM (1978) Selection and overgrowth of specifically and permanently drug-resistant tumor cells. Exp Ther Kinetics 15: 207–217

    CAS  Google Scholar 

  50. Smolev JK, Heston WDW, Scott WW, Coffey DS (1977) Characterization of the Dunning R-3327-H prostatic adenocarcinoma: An appropriate animal model for prostatic cancer. Cancer Treat Rep 61: 273–287

    Google Scholar 

  51. Trachtenberg J, Bujnovszky P, Walsh PC (1982) Androgen receptor content of normal and hyperplastic human prostate. J Clin Endocrinol Metab 54: 17–21

    Article  PubMed  CAS  Google Scholar 

  52. Veterans Administration Co-operative Urological Research Group (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011–1017

    Google Scholar 

  53. Wagner RK (1972) Characterization and assay of steroid hormone receptors and steroid binding serum proteins by agar gel electrophoresis at low temperature. Hoppe Seylers Z Physiol Chem 253: 1235–1245

    Article  Google Scholar 

  54. Walsh PC (1975) Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 2: 125–140

    PubMed  CAS  Google Scholar 

  55. Walsh PC, Hicks LL (1979) Characterization and measurement of androgen receptors in human prostatic tissue. Prog Clin Biol Res 33: 51–63

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. G. Bartsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. J. Oefner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Urologische Klinik und Poliklinik, Universität Würzburg, Luitpoldkrankenhaus, Josef-Schneider-Straße 2, D-8700, Würzburg, Deutschland

    H. G. W. Frohmüller  & M. P. Wirth  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Bartsch, G., Oefner, P.J. (1990). Grundlagen und Grenzen der endokrinen Therapie des fortgeschrittenen Prostatakarzinoms. In: Frohmüller, H.G.W., Wirth, M.P. (eds) Behandlung des fortgeschrittenen Prostatakarzinoms. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84064-7_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-84064-7_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-52076-4

  • Online ISBN: 978-3-642-84064-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation